Gilead Sciences and Everest Medicines have jointly reported that sacituzumab govitecan met the primary goal of overall response rate (ORR) in the Phase IIb EVER-132-001 clinical trial of metastatic triple-negative breast cancer (TNBC) patients.
Marketed in the US as Trodelvy, sacituzumab govitecan is an antibody and topoisomerase inhibitor conjugate that acts on the Trop-2 receptor.
Under a licensing deal with Gilead, Everest holds exclusive rights to develop and market the drug for various cancers in Greater China, South Korea and some nations in South-East Asia.
The multicentre, single arm, registrational trial is analysing sacituzumab govitecan in a total of 80 adult subjects with unresectable locally advanced or metastatic TNBC in China.
These patients were already treated with two or more previous systemic therapies, at least one for metastatic disease.
Findings showed that ORR was 38.8%, as assessed by an Independent Review Committee.
The safety profile of the drug was also in line with previously reported trials without any novel safety signals detected.
Gilead noted that the latest data was consistent with findings observed in the international Phase III ASCENT trial.
Everest Medicines Oncology chief medical officer Yang Shi said: “These topline results confirm that sacituzumab govitecan has the potential to help change the treatment outlook for people in China living with mTNBC.
“These data, along with the benefit seen in the global ASCENT study, support its potential as a novel treatment for patients who currently have extremely limited options.”
Last month, Gilead and Merck (MSD) entered a clinical trial partnership and supply agreement to evaluate the efficacy of Trodelvy, along with the latter’s Keytruda (pembrolizumab) for TNBC treatment.
The companies will analyse the combination as first-line therapy to treat locally advanced or metastatic TNBC patients.